Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,406.00DKK
24 Mar 2017
Change (% chg)

kr.12.00 (+0.86%)
Prev Close
kr.1,394.00
Open
kr.1,404.00
Day's High
kr.1,409.00
Day's Low
kr.1,387.00
Volume
215,974
Avg. Vol
291,212
52-wk High
kr.1,489.00
52-wk Low
kr.838.50

GEN.CO

Chart for GEN.CO

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.28
Market Cap(Mil.): kr.84,664.79
Shares Outstanding(Mil.): 60.74
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 72.68 47.82 29.72
EPS (TTM): 19.18 -- --
ROI: 28.55 -2.46 13.00
ROE: 28.56 5.18 14.15

BRIEF-Genmab: CHMP issues positive opinion recommending DARZALEX (daratumumab)

* CHMP issued positive opinion for DARZALEX for relapsed or refractory multiple myeloma

Feb 24 2017

Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

CORRECTED-Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters.

Feb 22 2017

BRIEF-Genmab FY operating income up to DKK 1,053 million

* Revenue was 1,816 million Danish crowns ($257.45 million) in 2016 compared to 1,133 million crowns in 2015

Feb 22 2017

BRIEF-Genmab raises 2016 financial guidance

* Raises its 2016 financial guidance published on Dec. 20, 2016

Feb 06 2017

BRIEF-Genmab: net sales of Darzalex in 2016 $572 million

* Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Source text for Eikon:

Jan 24 2017

Genmab shares hit record high as U.S. widens use of cancer drug

COPENHAGEN, Nov 22 Shares in Danish biotech company Genmab jumped to a record high on Tuesday after U.S. regulators approved widening the use its blood cancer drug Darzalex, prompting the firm to raise financial guidance for the year.

Nov 22 2016

BRIEF-Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma

* Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma and updates financial guidance

Nov 21 2016

More From Around the Web

Earnings vs. Estimates